Onbevzi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/02/2023 
09/03/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
13/10/2022 
09/12/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02202 
bevacizumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/403/202202. 
IB/0004/G 
This was an application for a group of variations. 
21/07/2022 
09/12/2022 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
02102 
bevacizumab 
WS/2040/G 
This was an application for a group of variations 
06/05/2021 
24/06/2022 
SmPC and PL 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
Page 3/3 
 
 
 
 
 
 
 
